» Articles » PMID: 35408893

Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APP Alzheimer's Disease Mouse Model

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Apr 12
PMID 35408893
Authors
Affiliations
Soon will be listed here.
Abstract

The free fatty acid FFA3 receptor (FFA3R) belongs to the superfamily of G-protein-coupled receptors (GPCRs). In the intestine and adipose tissue, it is involved in the regulation of energy metabolism, but its function in the brain is unknown. We aimed, first, to investigate the expression of the receptor in the hippocampus of Alzheimer disease (AD) patients at different stages of the disease and, second, to assess whether genetic inactivation of the Ffar3 gene could affect the phenotypic features of the APP mouse model. The expression of transcripts for FFA receptors in postmortem human hippocampal samples and in the hippocampus of wild-type and transgenic mice was analyzed by RT-qPCR. We generated a double transgenic mouse, FFA3R/APP, to perform cognition studies and to assess, by immunoblotting Aβ and tau pathologies and the differential expression of synaptic plasticity-related proteins. For the first time, the occurrence of the FFA3R in the human hippocampus and its overexpression, even in the first stages of AD, was demonstrated. Remarkably, FFA3R/APP mice do not have the characteristic memory impairment of 12-month-old APP mice. Additionally, this newly generated transgenic line does not develop the most important Alzheimer's disease (AD)-related features, such as amyloid beta (Aβ) brain accumulations and tau hyperphosphorylation. These findings are accompanied by increased levels of the insulin-degrading enzyme (IDE) and lower activity of the tau kinases GSK3β and Cdk5. We conclude that the brain FFA3R is involved in cognitive processes and that its inactivation prevents AD-like cognitive decline and pathological hallmarks.

Citing Articles

Olfactory receptors in neural regeneration in the central nervous system.

Franco R, Garrigos C, Capo T, Serrano-Marin J, Rivas-Santisteban R, Lillo J Neural Regen Res. 2024; 20(9):2480-2494.

PMID: 39503417 PMC: 11801295. DOI: 10.4103/NRR.NRR-D-24-00495.


The Cognitive Improvement and Alleviation of Brain Hypermetabolism Caused by FFAR3 Ablation in Tg2576 Mice Is Persistent under Diet-Induced Obesity.

Solas M, Zamarbide M, Ardanaz C, Ramirez M, Perez-Mediavilla A Int J Mol Sci. 2022; 23(21).

PMID: 36362376 PMC: 9654726. DOI: 10.3390/ijms232113591.


Robustness of the Krebs Cycle under Physiological Conditions and in Cancer: New Clues for Evaluating Metabolism-Modifying Drug Therapies.

Franco R, Serrano-Marin J Biomedicines. 2022; 10(5).

PMID: 35625935 PMC: 9138339. DOI: 10.3390/biomedicines10051199.

References
1.
Hou Y, Shan C, Zhuang S, Zhuang Q, Ghosh A, Zhu K . Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease. Microbiome. 2021; 9(1):34. PMC: 7849090. DOI: 10.1186/s40168-020-00988-6. View

2.
Dunah A, Wang Y, Yasuda R, Kameyama K, Huganir R, Wolfe B . Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol. 2000; 57(2):342-52. View

3.
Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Perez-Roldan J, Garcia-Barroso C . Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease. Br J Pharmacol. 2011; 164(8):2029-41. PMC: 3246665. DOI: 10.1111/j.1476-5381.2011.01517.x. View

4.
Poitout V . Fatty Acids and Insulin Secretion: From FFAR and Near?. Diabetes. 2018; 67(10):1932-1934. DOI: 10.2337/dbi18-0027. View

5.
Rabbito A, Dulewicz M, Kulczynska-Przybik A, Mroczko B . Biochemical Markers in Alzheimer's Disease. Int J Mol Sci. 2020; 21(6). PMC: 7139967. DOI: 10.3390/ijms21061989. View